JP2019214620A5 - - Google Patents

Download PDF

Info

Publication number
JP2019214620A5
JP2019214620A5 JP2019171346A JP2019171346A JP2019214620A5 JP 2019214620 A5 JP2019214620 A5 JP 2019214620A5 JP 2019171346 A JP2019171346 A JP 2019171346A JP 2019171346 A JP2019171346 A JP 2019171346A JP 2019214620 A5 JP2019214620 A5 JP 2019214620A5
Authority
JP
Japan
Prior art keywords
pge
hsc
cellular
transplant
cellular transplant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2019171346A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019214620A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2019214620A publication Critical patent/JP2019214620A/ja
Publication of JP2019214620A5 publication Critical patent/JP2019214620A5/ja
Priority to JP2021170835A priority Critical patent/JP2022025091A/ja
Withdrawn legal-status Critical Current

Links

JP2019171346A 2006-03-24 2019-09-20 造血性幹細胞の増殖を調節する方法 Withdrawn JP2019214620A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021170835A JP2022025091A (ja) 2006-03-24 2021-10-19 造血性幹細胞の増殖を調節する方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78596806P 2006-03-24 2006-03-24
US60/785,968 2006-03-24

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2019027038A Division JP6797222B2 (ja) 2006-03-24 2019-02-19 造血性幹細胞の増殖を調節する方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021170835A Division JP2022025091A (ja) 2006-03-24 2021-10-19 造血性幹細胞の増殖を調節する方法

Publications (2)

Publication Number Publication Date
JP2019214620A JP2019214620A (ja) 2019-12-19
JP2019214620A5 true JP2019214620A5 (cg-RX-API-DMAC10.html) 2020-11-12

Family

ID=38526581

Family Applications (8)

Application Number Title Priority Date Filing Date
JP2009501606A Expired - Fee Related JP5247675B2 (ja) 2006-03-24 2007-03-26 造血性幹細胞の増殖を調節する方法
JP2013046473A Expired - Fee Related JP6041711B2 (ja) 2006-03-24 2013-03-08 造血性幹細胞の増殖を調節する方法
JP2015147317A Active JP6208719B2 (ja) 2006-03-24 2015-07-27 造血性幹細胞の増殖を調節する方法
JP2016175313A Expired - Fee Related JP6530732B2 (ja) 2006-03-24 2016-09-08 造血性幹細胞の増殖を調節する方法
JP2019027038A Expired - Fee Related JP6797222B2 (ja) 2006-03-24 2019-02-19 造血性幹細胞の増殖を調節する方法
JP2019171346A Withdrawn JP2019214620A (ja) 2006-03-24 2019-09-20 造血性幹細胞の増殖を調節する方法
JP2021170835A Pending JP2022025091A (ja) 2006-03-24 2021-10-19 造血性幹細胞の増殖を調節する方法
JP2023098876A Pending JP2023112027A (ja) 2006-03-24 2023-06-16 造血性幹細胞の増殖を調節する方法

Family Applications Before (5)

Application Number Title Priority Date Filing Date
JP2009501606A Expired - Fee Related JP5247675B2 (ja) 2006-03-24 2007-03-26 造血性幹細胞の増殖を調節する方法
JP2013046473A Expired - Fee Related JP6041711B2 (ja) 2006-03-24 2013-03-08 造血性幹細胞の増殖を調節する方法
JP2015147317A Active JP6208719B2 (ja) 2006-03-24 2015-07-27 造血性幹細胞の増殖を調節する方法
JP2016175313A Expired - Fee Related JP6530732B2 (ja) 2006-03-24 2016-09-08 造血性幹細胞の増殖を調節する方法
JP2019027038A Expired - Fee Related JP6797222B2 (ja) 2006-03-24 2019-02-19 造血性幹細胞の増殖を調節する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021170835A Pending JP2022025091A (ja) 2006-03-24 2021-10-19 造血性幹細胞の増殖を調節する方法
JP2023098876A Pending JP2023112027A (ja) 2006-03-24 2023-06-16 造血性幹細胞の増殖を調節する方法

Country Status (10)

Country Link
US (7) US8168428B2 (cg-RX-API-DMAC10.html)
EP (3) EP1999255A2 (cg-RX-API-DMAC10.html)
JP (8) JP5247675B2 (cg-RX-API-DMAC10.html)
CN (2) CN101495623B (cg-RX-API-DMAC10.html)
AU (1) AU2007230902B2 (cg-RX-API-DMAC10.html)
CA (1) CA2647201C (cg-RX-API-DMAC10.html)
MX (3) MX373998B (cg-RX-API-DMAC10.html)
RU (2) RU2493252C2 (cg-RX-API-DMAC10.html)
WO (1) WO2007112084A2 (cg-RX-API-DMAC10.html)
ZA (2) ZA200808123B (cg-RX-API-DMAC10.html)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1999255A2 (en) 2006-03-24 2008-12-10 The Children's Medical Center Corporation Method to modulate hematopoietic stem cell growth
EP3824885A1 (en) 2006-10-20 2021-05-26 Children's Medical Center Corporation Method to enhance tissue regeneration
EP2094839B1 (en) * 2006-12-08 2020-02-05 University of Rochester Expansion of hematopoietic stem cells
EP2798956A1 (en) * 2007-04-23 2014-11-05 Stowers Institute for Medical Research Methods and compositions for hematopoeitic stem cell self-renewal
US8871752B2 (en) * 2008-02-19 2014-10-28 Sucampo Ag Method for modulating stem cell growth
ITUD20080058A1 (it) 2008-03-18 2009-09-19 Thankstem S R L Kit per la raccolta di sangue, preferibilmente periferico, per la produzione di cellule staminali
WO2009155041A2 (en) * 2008-05-28 2009-12-23 Children's Medical Center Corporation Method to modulate hematopoietic stem cell growth
EP3031907B1 (en) * 2008-11-06 2021-01-06 Indiana University Research and Technology Corporation Materials and methods to enhance hematopoietic stem cells engraftment procedures
WO2010096264A2 (en) 2009-02-03 2010-08-26 Children's Medical Center Corporation Methods for enhancing hematopoietic stem/progenitor cell engraftment
WO2010091052A2 (en) 2009-02-03 2010-08-12 Children's Medical Center Corporation Methods for enhancing hematopoietic stem/progenitor cell engraftment
EP3533445A1 (en) * 2009-03-19 2019-09-04 Fate Therapeutics, Inc. Compositions comprising cyclic amp enhancers and/or ep ligands, and methods of preparing and using the same
WO2010121122A2 (en) * 2009-04-17 2010-10-21 The Brigham And Women's Hospital, Inc. Biomechanical induction of hematopoiesis
EP2251010A1 (en) 2009-05-08 2010-11-17 Sygnis Bioscience GmbH & Co. KG Use of thiabendazole and derivatives thereof for the therapy of neurological conditions
US11459545B2 (en) 2009-11-15 2022-10-04 Indiana University Research And Technology Corporation Methods to enhance delivery and engraftment of stem cells including the identification of specific prostaglandin E2 receptors
US20130129686A1 (en) * 2009-11-19 2013-05-23 Regents Of The University Reducing Inflammation Using Cell Therapy
JP2013528373A (ja) * 2010-05-10 2013-07-11 フェイト セラピューティクス，インコーポレイテッド 生物学的な用途のための容器
CN103167876B (zh) * 2010-08-12 2016-08-31 菲特治疗公司 改进的造血干细胞和祖细胞疗法
PL2663313T3 (pl) * 2011-01-13 2019-01-31 SciPharm S.à r.l. Sposób zwiększania wszczepiania hematopoetycznych komórek macierzystych
WO2012149547A1 (en) * 2011-04-28 2012-11-01 Duke University Methods of treating hemoglobinopathies
CA2850484C (en) 2011-09-30 2021-01-26 Bluebird Bio, Inc. Compounds for improved viral transduction
EP2785350B1 (en) 2011-12-02 2018-05-02 Fate Therapeutics, Inc. Improved methods of treating ischemia
CN104066837B (zh) 2011-12-02 2020-12-08 菲特治疗公司 增强的干细胞组合物
US9428732B2 (en) 2011-12-05 2016-08-30 Primorigen Biosciences, Inc. Compositions and methods for differentiating pluripotent stem cells into primitive blood cells and uses thereof
WO2014015318A1 (en) * 2012-07-19 2014-01-23 Bluebird Bio, Inc. Soluble compounds for improved gene therapy methods
US9861685B2 (en) 2012-11-20 2018-01-09 Duke University Methods of treating hemoglobinopathies
US9943545B2 (en) * 2013-03-15 2018-04-17 Fate Therapeutics, Inc. Stem cell culture media and methods of enhancing cell survival
US10851412B2 (en) 2013-03-15 2020-12-01 Fate Therapeutics, Inc. Cell potency assay for therapeutic potential
US9428748B2 (en) * 2013-06-17 2016-08-30 Hong Gao Method of expanding hematopoietic stem cells
JP2015205835A (ja) * 2014-04-21 2015-11-19 国立大学法人福井大学 中性子線障害防護剤
CA2946747A1 (en) * 2014-04-23 2015-10-29 Texas Heart Institute Methods of enhancing stem cell engraftment
WO2016014794A1 (en) 2014-07-25 2016-01-28 Sangamo Biosciences, Inc. Methods and compositions for modulating nuclease-mediated genome engineering in hematopoietic stem cells
CN113699113A (zh) 2014-09-16 2021-11-26 桑格摩治疗股份有限公司 用于造血干细胞中核酸酶介导的基因组工程化和校正的方法和组合物
US10626372B1 (en) 2015-01-26 2020-04-21 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
JP6980534B2 (ja) 2015-06-25 2021-12-15 ザ チルドレンズ メディカル センター コーポレーション 造血幹細胞の増大、富化、および維持に関する方法および組成物
BR112018001232A2 (pt) 2015-07-21 2018-09-25 The Children's Medical Center Corporation pd-l1 que expressa células-tronco hematopoéticas e usos
CN105296427A (zh) * 2015-10-23 2016-02-03 深圳爱生再生医学科技有限公司 造血干细胞的体外扩增培养方法
JP7189587B2 (ja) * 2015-10-30 2022-12-14 典正 三浦 メチル化関連酵素ｈａｔ１とｋａｔ８の阻害薬
CN122146606A (zh) 2015-11-04 2026-06-05 菲特治疗公司 用于诱导造血细胞分化的方法和组合物
US12642852B1 (en) 2015-11-04 2026-06-02 Fate Therapeutics, Inc. Genomic engineering of pluripotent cells
KR20250134722A (ko) 2016-02-12 2025-09-11 블루버드 바이오, 인코포레이티드. Vcn 인핸서 조성물 및 이의 사용 방법
CN108883136A (zh) 2016-02-12 2018-11-23 蓝鸟生物公司 Vcn增强子组合物及其使用方法
EP4538365A3 (en) * 2016-03-04 2025-07-30 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for muscle regeneration using prostaglandin e2
WO2017161001A1 (en) 2016-03-15 2017-09-21 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion
WO2018093797A1 (en) 2016-11-15 2018-05-24 The Schepens Eye Research Institute, Inc. Compositions and methods for the treatment of aberrant angiogenesis
EP3634425A4 (en) * 2017-06-07 2021-04-07 Academia Sinica METHOD OF ELIMINATION OF UNDIFFERENTIATED PLURIPOTENT STEM CELLS
GB2578539B (en) 2017-06-09 2022-08-10 Univ Leland Stanford Junior Compositions and methods for preventing or treating muscle conditions
US12215351B2 (en) 2017-08-22 2025-02-04 The Children's Medical Center Corporation Methods for inducing hematopoietic stem cell specificity
WO2019060708A1 (en) 2017-09-22 2019-03-28 The Children's Medical Center Corporation TREATMENT OF TYPE 1 DIABETES AND AUTOIMMUNE DISEASES OR DISORDERS
CA3082643A1 (en) 2017-11-14 2019-05-23 The Schepens Eye Research Institute, Inc. Runx1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition
EP3597211A1 (en) 2018-07-19 2020-01-22 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Periostin compounds for the treatment of haematological complications
CN109609455A (zh) * 2018-12-28 2019-04-12 诺未科技（北京）有限公司 扩增造血干细胞的培养体系、方法及其用途
WO2020167948A1 (en) * 2019-02-13 2020-08-20 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for stem cell therapy
CN110051839A (zh) * 2019-04-16 2019-07-26 诺航生物技术(徐州)有限公司 一种促进脐带血干细胞体外扩增和增强脐带血干细胞移植后造血重建功能的药物
JP7853100B2 (ja) 2019-06-05 2026-04-28 オーチャード セラピューティクス（ヨーロッパ）リミテッド 真核細胞を修飾するための組成物及び方法
FI130749B1 (en) * 2020-01-24 2024-02-26 Faron Pharmaceuticals Oy USE OF VAP-1 INHIBITOR IN THE EX VIVO CULTURE OF HEMATOPOEITIC STEM CELLS AND IN THE TREATMENT OF BONE Marrow Loss or BONE Marrow Dysfunction
WO2021216378A1 (en) 2020-04-23 2021-10-28 The Schepens Eye Research Institute, Inc. Methods and materials for treatment of fibrosis
EP4146797A1 (en) 2020-05-06 2023-03-15 Orchard Therapeutics (Europe) Limited Treatment for neurodegenerative diseases
US11883436B2 (en) 2020-08-17 2024-01-30 The Board Of Trustees Of The University Of Illinois Method of preparing hematopoietic stem and progenitor cells for transplantation
AU2021202658A1 (en) 2021-04-28 2022-11-17 Fondazione Telethon Gene therapy
GB202206346D0 (en) 2022-04-29 2022-06-15 Ospedale San Raffaele Srl Gene therapy
WO2023244470A1 (en) * 2022-06-14 2023-12-21 The Children's Medical Center Corporation Surface calr chemical inducers
KR20240136869A (ko) 2023-03-07 2024-09-19 인제대학교 산학협력단 조혈 줄기세포 증식 또는 가동화 촉진용 조성물 및 가동화 조혈 줄기세포 수집방법
CN116355836B (zh) * 2023-04-07 2026-05-19 上海市东方医院（同济大学附属东方医院） 胆管树干细胞的扩增或传代体系及其应用
US20250332260A1 (en) 2024-04-10 2025-10-30 Garuda Therapeutics, Inc. Immune compatible cells for allogeneic cell therapies to cover global, ethnic, or disease-specific populations

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA103846A (en) 1906-12-03 1907-02-26 William Bell Manufacture of half-tone printing blocks
US3217903A (en) 1961-01-19 1965-11-16 Mc Graw Edison Co Segregating control
US3753357A (en) 1970-12-14 1973-08-21 Ovitron Res Corp Method and apparatus for the preservation of cells and tissues
US4199022A (en) 1978-12-08 1980-04-22 The United States Of America As Represented By The Department Of Energy Method of freezing living cells and tissues with improved subsequent survival
US4239679A (en) 1979-06-27 1980-12-16 Diamond Shamrock Corporation High bulk density rigid poly(vinyl chloride) resin powder composition and preparation thereof
HU181154B (en) 1980-07-18 1983-06-28 Epitestudomanyi Intezet Shaped building unit and space limiting or dividing structure made of same as well as method for producing the shaped building unit
US4559298A (en) 1982-11-23 1985-12-17 American National Red Cross Cryopreservation of biological materials in a non-frozen or vitreous state
US5004681B1 (en) 1987-11-12 2000-04-11 Biocyte Corp Preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood
EP0676470A1 (en) * 1989-10-16 1995-10-11 Amgen Inc. Stem cell factor
US5114672A (en) 1990-08-27 1992-05-19 Cryo-Cell International, Inc. Method for preserving blood fluid
AU702871B2 (en) * 1993-08-23 1999-03-11 Nexell Therapeutics Inc. (In vitro) growth of neutrophil and megakaryocyte precursors in serum-free media
AU6125396A (en) * 1995-06-07 1996-12-30 Novartis Ag Serum-free media for primitive hematopoietic cells and metho ds of use thereof
US6372796B1 (en) 1996-11-13 2002-04-16 Cold Spring Harbor Laboratory Therapeutic uses for nitric oxide inhibitors
GB9904281D0 (en) 1999-02-24 1999-04-21 Reneuron Ltd Transplantation
TWI247606B (en) 1999-11-24 2006-01-21 Ono Pharmaceutical Co Treating agent for osteopenic diseases
BR0015781A (pt) 1999-11-24 2002-12-31 Ono Pharmaceutical Co Composição farmacêutica para tratamento de doenças associadas à diminuição de massa óssea
US6226997B1 (en) 1999-12-07 2001-05-08 Cryo-Cell International, Inc. Method and device for maintaining temperature integrity of cryogenically preserved biological samples
US6852534B2 (en) 2000-11-03 2005-02-08 Kourion Therapeutics Gmbh Method to determine an engrafting cell dose of hematopoietic stem cell transplant units
JP4077158B2 (ja) 2001-01-10 2008-04-16 株式会社メニコン 植物性繊維分解剤およびそれを用いた植物性廃棄物の処理法
AU2002251935B2 (en) 2001-02-14 2007-11-29 Celularity Inc. Post-partum mammalian placenta, its use and placental stem cells therefrom
FR2825261B1 (fr) 2001-06-01 2003-09-12 Maco Pharma Sa Ligne de prelevement du sang placentaire comprenant une poche de rincage
US7179643B2 (en) 2001-06-14 2007-02-20 Reliance Life Sciences Pvt. Ltd. Device and a process for expansion of haemopoeitic stem cells for therapeutic use
US8021876B2 (en) 2001-11-15 2011-09-20 Children's Medical Center Corporation Methods of isolation, expansion and differentiation of fetal stem cells from chorionic villus, amniotic fluid, and placenta and therapeutic uses thereof
AU2002350352A1 (en) * 2001-12-21 2003-07-15 Mount Sinai Hospital Cellular compositions and methods of making and using them
RU2205627C1 (ru) * 2002-05-30 2003-06-10 Открытое акционерное общество "Косметическое объединение "Свобода" Крем для лица, выводящий токсины
HUE029417T2 (en) 2002-10-10 2017-02-28 Ono Pharmaceutical Co Microspheres containing ONO-1301
AU2004216898A1 (en) 2003-03-04 2004-09-16 Pfizer Products Inc. Use of EP2 selective receptor agonists in medical treatment
EP1601759A4 (en) * 2003-03-07 2007-02-14 Gamida Cell Ltd EXPANSION OF RENEWABLE STEM CELL POPULATIONS USING PI-3 KINASE MODULATORS
JP4865541B2 (ja) 2003-04-08 2012-02-01 イエダ リサーチ アンド ディベロップメント カンパニー リミテッド 化学誘引物質に対する増大させた感受性を有する幹細胞およびそれを産生および使用する方法
GB0324523D0 (en) * 2003-10-21 2003-11-26 Medical Res Council Compositions and methods of treatment
US8309608B2 (en) 2003-11-06 2012-11-13 Sanofi-Aventis Deutschland Gmbh Use of eNOS transcription enhancers in the cell therapy of ischemic heart diseases
IL158868A0 (en) 2003-11-13 2004-05-12 Yeda Res & Dev Methods of generating and using stem cells enriched with immature primitive progenitor
CA2573176A1 (en) * 2004-07-09 2006-01-19 Bc Cancer Agency Nup98-hox fusions for expansion of hemopoietic stem cells
US7147626B2 (en) 2004-09-23 2006-12-12 Celgene Corporation Cord blood and placenta collection kit
WO2006078886A2 (en) 2005-01-18 2006-07-27 Irm Llc Compounds and compositions as wnt signaling pathway modulators
EP1859028B1 (en) 2005-02-10 2015-12-02 Regents Of The University Of Minnesota Vascular endothelial cells
US20080194024A1 (en) 2005-07-29 2008-08-14 Mays Robert W Culture of Non-Embryonic Cells at High Cell Density
JP4562618B2 (ja) 2005-08-18 2010-10-13 陽一 佐藤 空き缶処理車
GB2447191B (en) * 2005-12-22 2011-08-03 Es Cell Int Pte Ltd Direct differentiation of cardiomyocytes from human embryonic stem cells
EP1999255A2 (en) 2006-03-24 2008-12-10 The Children's Medical Center Corporation Method to modulate hematopoietic stem cell growth
WO2007148332A1 (en) 2006-06-22 2007-12-27 Yeda Resaerch And Development Co. Ltd Catecholamine receptor modulation
WO2008021475A2 (en) 2006-08-16 2008-02-21 The General Hospital Corporation Compositions and methods for hematopoietic stem cell expansion or for modulating angiogenesis
KR20080042761A (ko) 2006-11-10 2008-05-15 문찬일 렙틴을 이용한 줄기세포 증식방법
EP2094839B1 (en) * 2006-12-08 2020-02-05 University of Rochester Expansion of hematopoietic stem cells

Similar Documents

Publication Publication Date Title
JP2022025091A5 (cg-RX-API-DMAC10.html)
Frenette et al. Mesenchymal stem cell: keystone of the hematopoietic stem cell niche and a stepping-stone for regenerative medicine
Bakhshi et al. Mesenchymal stem cells from the Wharton's jelly of umbilical cord segments provide stromal support for the maintenance of cord blood hematopoietic stem cells during long‐term ex vivo culture
HRP20201487T1 (hr) Stvaranje banke stanica strome mezenhima iz mononuklearnih stanica prikupljenih iz više donora koštane srži
WO2012088157A3 (en) Glp-1 receptor agonists for islet cell transplantation
JP2009526784A5 (cg-RX-API-DMAC10.html)
CN104082277A (zh) 一种人外周血单个核细胞的冻存保护剂及保存方法
BR112018072701A2 (pt) métodos de tratamento de leucemia mieloide aguda e mieloma múltiplo usando células exterminadoras naturais
Svalgaard et al. Low‐molecular‐weight carbohydrate Pentaisomaltose may replace dimethyl sulfoxide as a safer cryoprotectant for cryopreservation of peripheral blood stem cells
RU2011115827A (ru) Способ модулирования гематопоэтических стволовых клеток
US20250235482A1 (en) Production and therapeutic use of off-the-shelf double negative t cells
Baron et al. Clinical manufacturing of regulatory T cell products for adoptive cell therapy and strategies to improve therapeutic efficacy
JP2015517520A5 (cg-RX-API-DMAC10.html)
BR112021021349A2 (pt) Métodos de fabricação de células car t alogênicas
Demirci et al. Ex vivo culture resting time impacts transplantation outcomes of genome-edited human hematopoietic stem and progenitor cells in xenograft mouse models
Stanevsky et al. Double umbilical cord blood transplant: more than a cell dose?
Issa et al. The potential role for regulatory T-cell therapy in vascularized composite allograft transplantation
Midena et al. Nanoengineered 3D culture substrate enables superior persistence and polyclonal engraftment of genetically engineered hematopoietic stem cells
JP2009517078A5 (cg-RX-API-DMAC10.html)
JP2018537440A5 (cg-RX-API-DMAC10.html)
Beksac et al. Modalities to improve cord blood engraftment
Becnel et al. Current and future status of stem cell expansion
Pimanda Generating Multipotent Stem Cells From Primary Human Adipocytes for Tissue Repair
Pinho et al. Imaging Hematopoietic Stem Cells in Their Native Bone Marrow Microenvironment
Petrenko et al. Cryopreservation of mesenchymal stromal cells within wide-porous three-dimensional alginate-gelatin scaffolds